Eligibility criteria
| Inclusion criteria | Exclusion criteria |
| Aged 5 to 15 years | Hospital admission (≥24 h) for asthma in the last 12 months |
| Doctor diagnosis of asthma (parent/participant or doctor-reported) AND | Self-reported use of >6 SABA inhalers in the last 12 months (i.e. poor-control) |
| SABA use on three or more consecutive days in the last 12 months, AND/OR | Any use of ICS, LABA, LTRA, theophylline, anticholinergic agent or cromone in the last 6 months |
| SABA use on two or more days per month, on average, in the last 12 months, AND/OR | Any use of systemic corticosteroids in the last 6 weeks |
| Urgent medical review for worsening asthma in the last 12 months | Any medical condition which, at the Investigator's discretion, may present a safety risk or impact the feasibility of the study or the study results (including, but not limited to, other significant respiratory comorbidities, such as cystic fibrosis and bronchiectasis) |
| Registered with a General Practitioner | Any known or suspected contraindications to the medications prescribed in the study or their respective excipients |
| Previous life-threatening asthma (intensive care unit admission) | |
| Unable or unwilling to switch from current asthma treatment regimen | |
| Unable or unwilling to provide written informed consent (parent(s)/guardian(s)) or assent/consent (participant) | |
| Self-reported current pregnancy or breastfeeding at the time of enrolment |
SABA: short-acting β2-agonist; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene receptor antagonist.